Hepatitis C virus and human immunodeficiency virus co-infection;La co-infection par les virus de l'hépatite C et de l'immunodéficience humaine

Gastroenterologie Clinique et Biologique

Volumn 25, Issue 4 SUPPL., 2001, Pages

  Pol, S ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; RIBAVIRIN;

COMORBIDITY; CONFERENCE PAPER; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MIXED INFECTION; MORTALITY; SEROLOGY; TOXIC HEPATITIS; VIREMIA;

ANTI-HIV AGENTS; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS, TOXIC; HIV INFECTIONS; HUMANS; VIREMIA;

EID: 0034922140     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections
2. Foie, voies biliaires et infection par le virus de l'immunodéficience humaine
3. Hepatitis C virus infection in patients infected with the human immunodeficiency virus
4. Co-infection of hepatitis C virus with immunodeficiency virus and progression to AIDS
5. Does hepatitis C virus co-infection accelerate clinical and immunological evolution of HIV-infected patients?
6. The association between hepatitis C virus and immunodeficiency virus disease progression in a cohort of hemophilic men
7. Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users
8. Maternal-infant transmission of hepatitis C virus and HIV infections: A possible interaction
9. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
10. Human immunodeficiency virus infection modifies the natural history of chronic parenterraly-acquired hepatitis C with an unusually rapid progression to cirrhosis
11. The natural history of parenterally-acquired chronic hepatitis C
12. Liver fibrosis progression in HIV-HCV co-infected patients
13. Mortalité par cirrhose virale C chez les patients infectés par le VIH dans les services de médecine interne et de pathologie infectieuse en 1997
14. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
15. The treatment of chronic hepatitis C with interferon in patients infected with the human immunodeficiency virus
16. Antiretroviral drugs for AIDS
17. Determinants of outcome of compensated hepatitis C virus-related cirrhosis
18. Pathobiologic effects of hepatitis C
19. The role of hepatitis C virus-specific cytotoxic T lymphocytes in chronic hepatitis C
20. Fulminant hepatitis on withdrawal of chemotherapy in carriers of hepatitis C virus
21. Hepatitis C virus genotype, tissue HCV antigens, hepatocellular expression of HLA-A, B, C and intercellular adhesion molecules. Clues to pathogenesis of hepatocellular damage and response to interferon treatment in patients with chronic hepatitis C
22. Rapidly evolving hepatitis C virus-associated cirrhosis in HIV co-infected patient in relation to antiretroviral tritherapy
23. Enhancement of hepatitis C virus replication and liver damage in HIV-co-infected malades on antiretroviral combination therapy
24. Rapidly evolving hepatitis C virus infection in HIV co infected patients treated with HAART
25. Hepatitis C virus-related fibrosing cholestatic hepatitis after renal transplantation
26. Impact of treatment with human immunodeficiency virus protease inhibitors on hepatitis C viremia in patients co-infected with HIV
27. Anti-HIV tritherapy does not modify HCV replication in co-infected subjects
28. Anti-protease inhibitor therapy decreases the liver fibrosis progression rate in HIV-HCV co-infected patients
29. Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients
30. Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection
31. Severe hepatitis in three AIDS patients treated by indinavir
32. Restoration of immunity to chronic hepatitis B infection in HIV-infected patient on protease inhibitor
33. Acute hepatitis in HIV-infected patients during ritonavir treatment
34. Hepatitis C virus associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: An immune restoration disease?
35. Differential effect of ritonavir and indinavir on immune response to hepatitis C virus in HIV-1 infected patients
36. Randomized trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
37. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
38. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C
39. Comparison of ribavirin and placebo in CDC groupe III human immunodeficiency virus infection
40. Ribavirin antagonizes the effect of azidothymidine on HIV replication
41. Ribavirin does not modify HIV replication in HCV-HIV co-infected subjects under antiretroviral regimen
42. Efficacy and safety of combination therapy with interferon-alpha2b and ribavirin for chronic hepatitis C in HIV-infected patients